10-QPeriod: Q3 FY2022

STRYKER CORP Quarterly Report for Q3 Ended Sep 30, 2022

Filed November 1, 2022For Securities:SYK

Summary

Stryker Corporation reported a solid third quarter for 2022, demonstrating resilience amidst a challenging macroeconomic environment. Net sales increased by 7.7% year-over-year, reaching $4,479 million, driven by strong unit volume growth across both its MedSurg and Neurotechnology and Orthopaedics and Spine segments. Despite inflationary pressures and supply chain disruptions impacting gross margins, the company maintained healthy operating income and significantly grew net earnings by 86.3% to $816 million, translating to diluted EPS of $2.14. This earnings growth was notably aided by a favorable tax settlement. The company also executed a significant strategic acquisition, completing the purchase of Vocera Communications for $2.6 billion, aiming to bolster its digital care coordination capabilities. While investing in future growth through R&D and strategic acquisitions, Stryker managed its cash flow effectively, although net cash from operations saw a decrease compared to the prior year, largely due to increased inventory build to mitigate supply chain risks. The company reaffirmed its financial strength and liquidity, positioning itself for continued growth.

Financial Highlights

50 data points
Beta

Revenue

$4.48B

62.1% Gross Margin

Net Income

$816.00M

18.2% Net Margin

EPS (Diluted)

$2.14

Total Assets

$35.98B

Cash & Equivalents

$1.42B

Free Cash Flow

$751.00M

Financial Statements
Beta
Revenue$4.48B
Cost of Revenue$1.70B
Gross Profit$2.78B
R&D Expenses$364.00M
SG&A Expenses$1.46B
Operating Expenses$1.97B
Operating Income$808.00M
Net Income$816.00M
EPS (Basic)$2.16
EPS (Diluted)$2.14
Shares Outstanding (Basic)378.40M
Shares Outstanding (Diluted)381.80M

Key Highlights

  • 1Stryker reported a 7.7% increase in net sales to $4,479 million for the third quarter of 2022, driven by strong unit volume growth in both key segments.
  • 2Net earnings surged by 86.3% to $816 million, with diluted EPS of $2.14, significantly boosted by favorable tax settlements.
  • 3The company completed the strategic acquisition of Vocera Communications for $2.6 billion, enhancing its digital care coordination offerings within the MedSurg and Neurotechnology segment.
  • 4Gross profit margin saw a slight contraction to 62.1% from 63.5% year-over-year, attributed to increased costs from electronic component purchases and general inflationary pressures.
  • 5Research, Development, and Engineering expenses increased by 19.0% for the quarter, reflecting continued investment in innovation and integration of acquisitions.
  • 6Net cash provided by operating activities decreased to $1,621 million for the nine months ended September 30, 2022, from $2,263 million in the prior year, primarily due to increased inventory build to manage supply chain issues.
  • 7Despite economic headwinds, Stryker ended the quarter with a strong balance sheet, including $1,420 million in cash and cash equivalents.

Frequently Asked Questions

Stryker reported a 7.7% increase in net sales for the third quarter of 2022, reaching $4,479 million. This growth was driven by an increase in unit volume across both the MedSurg and Neurotechnology and Orthopaedics and Spine segments, partially offset by foreign currency headwinds.

Inflationary pressures, particularly for electronic components, labor, steel, and transportation, along with supply chain disruptions, led to increased costs. This resulted in a slight contraction of the gross profit margin to 62.1% from 63.5% in the prior year's quarter. However, the company managed operating expenses effectively, and a favorable tax settlement significantly boosted net earnings.

The acquisition of Vocera Communications for $2.6 billion is a strategic move to enhance Stryker's digital care coordination and communication capabilities. Vocera is integrated into the MedSurg and Neurotechnology segment, aiming to expand Stryker's presence in adjacent markets and accelerate its digital transformation.

For the nine months ended September 30, 2022, net cash provided by operating activities was $1,621 million, a decrease from the prior year, mainly due to increased inventory to mitigate supply chain risks. The company's investing activities were significantly impacted by the Vocera acquisition. Despite these factors, Stryker maintains strong liquidity, with $1,420 million in cash and cash equivalents and has access to credit facilities and commercial paper programs.